ReP USP - Resultado da busca

Filtros : "Polônia" "REGO, EDUARDO MAGALHÃES" Removido: "WAITZBERG, DAN LINETZKY" Limpar

Filtros

Collaboration
Normalized affiliation
- harvard university (hu) (~1)
- universidade estadual de campinas (unicamp) (~1)
Non normalized affiliation
- asociación española primera de socorros mutuos, montevideo (1)
- clinica ruiz de puebla, puebla (1)
- dana farber cancer institute, boston (1)
- department of hematology, hospital 12 de octubre, madrid (1)
- erasmus university medical center, rotterdam (1)

Countries of institutions of collaboration
- alemanha (2)
- espanha (2)
- itália (2)
- polônia (2)
- brasil (1)

Artigo de periodico
All-trans retinoic acid with daunorubicin or idarubicin for risk-adapted treatment of acute promyelocytic leukaemia: a matched-pair analysis of the PETHEMA LPA-2005 and IC-APL studies (2015)
Sanz, Miguel A.; Montesinos, Pau; Kim, Haesook T.; Ruiz-Argüelles, Guillermo J.; Undurraga, María S.; Uriarte, María R.; Martínez, Lem; Jacomo, Rafael H.; Gutiérrez-Aguirre, Homero; Melo, Raul A. M.; Bittencourt, Rosane; Pasquini, Ricardo; Pagnano, Katia; Fagundes, Evandro M.; Vallenga, Edo; Holowiecka, Alexandra; González-Huerta, Ana J.; Fernández, Pascual; De La Serna, Javier; Brunet, Salut; De Lisa, Elena; González-Campos, José; Ribera, José M.; Krsnik, Isabel; Ganser, Arnold; Berliner, Nancy; Ribeiro, Raul C.; Lo-Coco, Francesco; Löwenberg, Bob; Rego, Eduardo Magalhães
Source: Annals of Hematology. Unidade: FMRP
Subjects: LEUCEMIA, VITAMINA A, QUIMIOTERÁPICOS
A citação é gerada automaticamente e pode não estar totalmente de acordo com as normas
ABNT
SANZ, Miguel A. et al. All-trans retinoic acid with daunorubicin or idarubicin for risk-adapted treatment of acute promyelocytic leukaemia: a matched-pair analysis of the PETHEMA LPA-2005 and IC-APL studies. Annals of Hematology, v. 94, n. 8, p. 1347-1356, 2015Tradução . . Disponível em: https://doi.org/10.1007/s00277-015-2393-0. Acesso em: 24 maio 2024.
APA
Sanz, M. A., Montesinos, P., Kim, H. T., Ruiz-Argüelles, G. J., Undurraga, M. S., Uriarte, M. R., et al. (2015). All-trans retinoic acid with daunorubicin or idarubicin for risk-adapted treatment of acute promyelocytic leukaemia: a matched-pair analysis of the PETHEMA LPA-2005 and IC-APL studies. Annals of Hematology, 94( 8), 1347-1356. doi:10.1007/s00277-015-2393-0
NLM
Sanz MA, Montesinos P, Kim HT, Ruiz-Argüelles GJ, Undurraga MS, Uriarte MR, Martínez L, Jacomo RH, Gutiérrez-Aguirre H, Melo RAM, Bittencourt R, Pasquini R, Pagnano K, Fagundes EM, Vallenga E, Holowiecka A, González-Huerta AJ, Fernández P, De La Serna J, Brunet S, De Lisa E, González-Campos J, Ribera JM, Krsnik I, Ganser A, Berliner N, Ribeiro RC, Lo-Coco F, Löwenberg B, Rego EM. All-trans retinoic acid with daunorubicin or idarubicin for risk-adapted treatment of acute promyelocytic leukaemia: a matched-pair analysis of the PETHEMA LPA-2005 and IC-APL studies [Internet]. Annals of Hematology. 2015 ; 94( 8): 1347-1356.[citado 2024 maio 24 ] Available from: https://doi.org/10.1007/s00277-015-2393-0
Vancouver
Sanz MA, Montesinos P, Kim HT, Ruiz-Argüelles GJ, Undurraga MS, Uriarte MR, Martínez L, Jacomo RH, Gutiérrez-Aguirre H, Melo RAM, Bittencourt R, Pasquini R, Pagnano K, Fagundes EM, Vallenga E, Holowiecka A, González-Huerta AJ, Fernández P, De La Serna J, Brunet S, De Lisa E, González-Campos J, Ribera JM, Krsnik I, Ganser A, Berliner N, Ribeiro RC, Lo-Coco F, Löwenberg B, Rego EM. All-trans retinoic acid with daunorubicin or idarubicin for risk-adapted treatment of acute promyelocytic leukaemia: a matched-pair analysis of the PETHEMA LPA-2005 and IC-APL studies [Internet]. Annals of Hematology. 2015 ; 94( 8): 1347-1356.[citado 2024 maio 24 ] Available from: https://doi.org/10.1007/s00277-015-2393-0
Artigo de periodico
Florence: a randomized, double-blind, phase III pivotal study of febuxostat versus allopurinol for the prevention of tumor lysis syndrome (TLS) in patients with hematologic malignancies at intermediate to high TLS risk (2015)
Spina, M.; Nagy, Z.; Ribera, J. M.; Federico, M.; Aurer, I.; Jordan, K.; Borsaru, G.; Pristupa, A. S.; Bosi, A.; Grosicki, S.; Glushko, N. L.; Ristic, D.; Jakucs, J.; Montesinos, P.; Mayer, J.; Rego, Eduardo Magalhães; Baldini, S.; Scartoni, S.; Capriati, A.; Maggi, C. A.; Simonelli, C.
Source: Annals of Oncology. Unidade: FMRP
Subjects: NEOPLASIAS, HEMATOLOGIA, RIM, ÁCIDO ÚRICO, DOENÇAS HEMATOLÓGICAS
A citação é gerada automaticamente e pode não estar totalmente de acordo com as normas
ABNT
SPINA, M. et al. Florence: a randomized, double-blind, phase III pivotal study of febuxostat versus allopurinol for the prevention of tumor lysis syndrome (TLS) in patients with hematologic malignancies at intermediate to high TLS risk. Annals of Oncology, v. 26, n. 10, p. 2155-2161, 2015Tradução . . Disponível em: https://doi.org/10.1093/annonc/mdv317. Acesso em: 24 maio 2024.
APA
Spina, M., Nagy, Z., Ribera, J. M., Federico, M., Aurer, I., Jordan, K., et al. (2015). Florence: a randomized, double-blind, phase III pivotal study of febuxostat versus allopurinol for the prevention of tumor lysis syndrome (TLS) in patients with hematologic malignancies at intermediate to high TLS risk. Annals of Oncology, 26( 10), 2155-2161. doi:10.1093/annonc/mdv317
NLM
Spina M, Nagy Z, Ribera JM, Federico M, Aurer I, Jordan K, Borsaru G, Pristupa AS, Bosi A, Grosicki S, Glushko NL, Ristic D, Jakucs J, Montesinos P, Mayer J, Rego EM, Baldini S, Scartoni S, Capriati A, Maggi CA, Simonelli C. Florence: a randomized, double-blind, phase III pivotal study of febuxostat versus allopurinol for the prevention of tumor lysis syndrome (TLS) in patients with hematologic malignancies at intermediate to high TLS risk [Internet]. Annals of Oncology. 2015 ; 26( 10): 2155-2161.[citado 2024 maio 24 ] Available from: https://doi.org/10.1093/annonc/mdv317
Vancouver
Spina M, Nagy Z, Ribera JM, Federico M, Aurer I, Jordan K, Borsaru G, Pristupa AS, Bosi A, Grosicki S, Glushko NL, Ristic D, Jakucs J, Montesinos P, Mayer J, Rego EM, Baldini S, Scartoni S, Capriati A, Maggi CA, Simonelli C. Florence: a randomized, double-blind, phase III pivotal study of febuxostat versus allopurinol for the prevention of tumor lysis syndrome (TLS) in patients with hematologic malignancies at intermediate to high TLS risk [Internet]. Annals of Oncology. 2015 ; 26( 10): 2155-2161.[citado 2024 maio 24 ] Available from: https://doi.org/10.1093/annonc/mdv317

Digital Library of Intellectual Production of Universidade de São Paulo 2012 - 2024